Straumann Holding AG (LON:0QMV)
London
· Delayed Price · Currency is GBP · Price in CHF 130.50
-2.00 (-1.51%)
At close: Feb 21, 2025
Straumann Holding AG Revenue
In the year 2024, Straumann Holding AG had annual revenue of 2.50B CHF with 9.98% growth. Straumann Holding AG had revenue of 1.23B in the half year ending December 31, 2024, with 7.72% growth.
Revenue
2.50B CHF
Revenue Growth
+9.98%
P/S Ratio
n/a
Revenue / Employee
225.39K CHF
Employees
11,109
Market Cap
18.30B GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.50B | 227.21M | 9.98% |
| Dec 31, 2023 | 2.28B | -44.10M | -1.90% |
| Dec 31, 2022 | 2.32B | 298.88M | 14.78% |
| Dec 31, 2021 | 2.02B | 596.05M | 41.80% |
| Dec 31, 2020 | 1.43B | -170.37M | -10.67% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.19B |
| GSK plc | 31.38B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| Hikma Pharmaceuticals | 2.39B |
| ConvaTec Group | 1.74B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |